The Oncotype DX (ODX) test is a 21-gene expression assay that assigns patients a risk recurrence score from 0 to 100 to identify cases of HR + /HER2- breast cancer that would most likely benefit from adjuvant chemotherapy3. The gene discussed is ERBB2; the disease is breast carcinoma.